Particulate drug delivery

a technology of particle and drug delivery, applied in the direction of powder delivery, microcapsules, cyclic peptide ingredients, etc., can solve the problems of complex biodistribution and pharmacokinetic responses in vivo, drug loading and encapsulation efficiency control, and significant toxicities, so as to facilitate particle entry into cells, facilitate particle targeting, and enhance particle stability

Inactive Publication Date: 2008-10-09
THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
View PDF18 Cites 100 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention describes how we have created small particles made up of different materials that can deliver medicine inside our body. These particles can be modified with various substances like antibodies, DNA, protein, or other compounds to make them better at finding their way to specific types of tissues or entering cells. This helps improve the effectiveness of the medication while making it safer because they don't harmful components along the way.

Problems solved by technology

The technical problem addressed in this patent text is how to control the formation of stable and efficient nanoparticles for drug delivery without causing burnt outcomes or uneven distribution of drug molecules. Existing techniques often resulted in low drug loadings and incomplete encapsulation of the drug molecules, making them unable to maintain their therapeutic activity in vivo. Additionally, previous research has shown that some types of nanoparticles had multi-modal distributions, indicating potential issues with particle heterogeneity. The present invention offers an improved approach through a simplified process for creating nanoconjugates with controlled drug loading and encapsulation efficiency.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Particulate drug delivery
  • Particulate drug delivery
  • Particulate drug delivery

Examples

Experimental program
Comparison scheme
Effect test

example 1

Polylactide-Paclitaxel Nanoconjugate Particles

[0111]Nanoparticle design of this invention is based on the use of drugs as initiators in ring-opening polymerization reactions to form drug-polymer (and drug-oligomer) conjugates in which the drug is covalently bonded to the polymer or oligomer. Because the drug is used as the initiator of polymerization, the efficiency of conjugation of the drug to the polymer (oligomer) will be very high, ideally 100%. Additionally, if all of the drug molecules are efficiently incorporated into a living polymerization (e.g. where drug molecules function as initiators), the drug loading percentage can be precisely controlled by adjusting the monomer / initiator ratio.

[0112]To initially demonstrate this strategy, paclitaxel (Ptxl) was used in the presence of an appropriate catalyst to initiate a living polymerization of lactide. Utilization of molecules containing hydroxyl groups as initiators for the ring-opening living polymerization of lactide is well ...

example 2

Polylactide-Doxorubicin Polymer (Doxo-PLA)

[0140]The catalyst (BDI)MgN(TMS)2 and D,L-lactide were treated as in Ptxl-PLA polymerization. The polymerization was conducted in a glove box. All the reaction vessels were covered with aluminum foil and the box light was turned off. First, doxorubicin was dissolved in DMF and stirred for 10 min, until it completely dissolved. (BDI)MgN(SiMe3)2 was then added to and dissolved in THF. The doxorubicin and (BDI)MgN(SiMe3)2 solutions were mixed for 15-20 min, and the solution changed color from orange red to purple. On HPLC analysis, the peak associated with doxorubicin shifted, indicating that a complex of (BDI)MgN(SiMe3)2 and doxorubicin was formed. The UV detector was at 450 nm. D,L-lactide was dissolved in THF and added dropwise into the mixture of doxorubicin and (BDI)MgN(SiMe3)2 with rapid stirring. The reaction process was monitored by HPLC until all of the doxorubicin was gone. The UV spectrum of Doxo-LA exhibited an absorption at 325-400...

example 3

Dtxl-PLA using 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) or BDI—Mg—N(TMS)2

[0141]The TBD or BDI—Mg—N(TMS)2 catalyst was mixed with docetaxel and the lactide was added to the mixture of catalyst and initiator. For example, docetaxel and TBD were dissolved in THF solution and stirred for 5-10 min. (In HPLC, the peak of docetaxel shifted, indicating the TBD formed complex with docetaxel). D,L-Lactide was dissolved in THF solution and added dropwise into the mixture of docetaxel and TBD. The reaction was similar to that of paclitaxel-PLA, monitored by FTIR and HPLC. Polymerization initiated by docetaxel-Mg(II) complex was carried out in the same way as described above for paclitaxel. Nanoparticles were formed similarly to Ptxl-LA nanoparticles.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Lengthaaaaaaaaaa
Sizeaaaaaaaaaa
Sizeaaaaaaaaaa
Login to view more

Abstract

Methods for efficient preparation of drug-polymer (or oligomer) conjugates which are useful in the preparation of particles, including microparticles and nanoparticles, for delivery of the drug in vivo for therapeutic applications. The invention additionally provides certain drug-polymer and drug-oligomer conjugates which are useful in the preparation of particles for delivery of the drug in vivo. The invention also provides nanoparticles of this invention prepared by nanoprecipitation using drug-polymer/oligomer conjugates of the invention.
The drug conjugates are formed during polymerization of the polymer or oligomer in which the drug is employed as an initiator of the polymerization of the monomers which form the polymer and/or oligomer. More specifically, the drug conjugates are formed by ring-opening polymerization of cyclic monomers in the presence of an appropriate ring-opening polymerization catalyst and the initiator (the drug). The method is particularly useful for formation of polymer/oligomer conjugates with drugs and other chemical species containing one or more hydroxyl groups or thiol groups.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap